This contract expires in 339 days (Sep 29, 2027).

Browse related active opportunities

UNIVERSITY OF ILLINOIS - THERAPEUTIC ROLE OF SOLUBLE ADENYLYL CYCLASE INHIBITION IN AMELIORATING INFLAMMATORY VASCULAR REMODELING IN PULMONARY ARTERIAL HYPERTENSION

PIID: 75N98026P01850
Signed Date: Sep 28, 2026Effective Date: Sep 30, 2026End Date: Closes in 339 days
Award $
$40K
Vendor
UNIVERSITY OF ILLINOIS
NAICS
541715
Signed Date
Sep 28, 2026

Key Details

Dollars Obligated
$39,789.08
Awarding Sub-Agency
National Institutes of Health
Product Service Code
Q301 - REFERENCE LABORATORY TESTING
Place of Performance
CHICAGO, IL

Description

THERAPEUTIC ROLE OF SOLUBLE ADENYLYL CYCLASE INHIBITION IN AMELIORATING INFLAMMATORY VASCULAR REMODELING IN PULMONARY ARTERIAL HYPERTENSION

Context & Analysis

On Sep 28, 2026, Department of Health and Human Services obligated $39,789.08 to UNIVERSITY OF ILLINOIS for therapeutic role of soluble adenylyl cyclase inhibition in ameliorating inflammatory vascular remodeling in pulmonary arterial hypertension. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY). Performance is located in CHICAGO, IL. The contract is scheduled through Sep 29, 2027 — approximately 11 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.

Contractor Information

UEI: W8XEAJDKMXH3
Location: CHICAGO, IL
View Full Record on USASpending.gov

Stay Updated

Get notified about new opportunities matching your interests.

Related